Drug Profile
Factor VIII gene therapy - Genetic Therapy
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Genetic Therapy
- Developer Genetic Therapy; Nonindustrial source
- Class Blood coagulation factors; Coagulants
- Mechanism of Action Blood coagulation factor replacements; Factor X stimulants; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Haemophilia
Most Recent Events
- 04 Dec 2003 No development reported - Preclinical for Haemophilia in USA (IV)
- 20 Jun 2001 Preclinical development for Haemophilia in USA (IV)
- 30 Jul 1998 No-Development-Reported for Haemophilia in USA (IV)